Group 1: Market Context - During stock-market corrections, investors are encouraged to take advantage of discounted stocks, as bull markets typically follow downturns, leading to potential long-term gains [1] - Companies often trade at steep discounts during corrections due to panic-selling by investors, creating opportunities for savvy investors [1] Group 2: Moderna - Moderna gained prominence by rapidly developing a COVID-19 vaccine but has faced revenue declines and returned to unprofitability as the pandemic recedes [3][8] - The company has made significant clinical advancements, including the approval of a vaccine for respiratory syncytial virus (RSV) and successful phase 3 studies for a combination COVID/influenza vaccine [5] - Moderna targets high unmet medical needs with a late-stage pipeline that includes a cytomegalovirus (CMV) vaccine and a personalized cancer vaccine, showcasing its innovative capabilities in the mRNA vaccine field [6][7] Group 3: Regeneron Pharmaceuticals - Regeneron Pharmaceuticals is experiencing uncertainty due to biosimilar competition for its key product Eylea, despite strong financial results last year [9][10] - The company’s Dupixent, an eczema treatment, has expanded its label to include chronic obstructive pulmonary disease (COPD), potentially adding billions in sales [11] - Regeneron is developing a new formulation of Eylea with a more convenient dosing schedule, which may mitigate losses from biosimilar competition [12] - The company has a promising pipeline in oncology, weight loss, and gene therapy for hearing loss, along with a new dividend and share-buyback program to reward shareholders [12][13]

In the latest trading session, Moderna (MRNA) closed at $27.19, marking a -0.75% move from the previous day. This change lagged the S&P 500's 0.74% gain on the day. On the other hand, the Dow registered a gain of 0.05%, and the technology-centric Nasdaq increased by 1.26%.The biotechnology company's stock has dropped by 14.73% in the past month, falling short of the Medical sector's loss of 7.7% and the S&P 500's loss of 4.77%.Investors will be eagerly watching for the performance of Moderna in its upcoming ...

Moderna (MRNA) is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat estimates by 7.06% in the last reported quarter. The Zacks Consensus Estimate for sales and earnings is pegged at $127 million and a loss of $2.91 per share, respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Factors Shaping MRNA’s Upcoming ResultsThe company is likely to have generated a major portion of its revenues from selling its COVID-19 va ...

Wall Street expects a year-over-year increase in earnings on lower revenues when Moderna (MRNA) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 1, 2025, might help the stock move higher if these key numbers are better than expectations. ...

Core Viewpoint - Moderna has experienced significant fluctuations in stock performance and earnings since the peak of its COVID-19 vaccine sales, but it has a promising pipeline of products that could lead to future growth [1][4][10] Group 1: Current Performance - Demand for COVID vaccinations has declined, impacting Moderna's revenue, which fell from a peak of over $19 billion in 2022 to $3.2 billion last year [4][2] - Moderna's stock has dropped more than 90% since its peak in 2021 due to disappointing earnings and performance [4][1] Group 2: Future Prospects - The company aims to bring as many as 10 products to market by 2027, including vaccines for cytomegalovirus (CMV), personalized cancer, and norovirus, all currently in phase 3 trials [5][6] - Moderna's clinical trial success rate is higher than the industry average, with an 83% probability of success for phase 3 trials compared to 69% for traditional biopharma [7] - The company predicts a compound annual growth rate of 25%, potentially increasing revenue to $6 billion by 2028 as new products are launched [8] Group 3: Research and Development Strategy - Moderna is adjusting its R&D investments, with respiratory vaccine research accounting for half of its investment from 2024 to 2025, and oncology research expected to rise significantly from 2026 to 2028 [9] - By 2030, Moderna is likely to have multiple products across various treatment areas, indicating a potential new phase of revenue growth [10]

Core Insights - The first quarter of 2025 was challenging for the S&P 500 and Nasdaq Composite, with losses of 4.6% and 10.4% respectively, impacting shares of Moderna which fell by 31.8% [1] - Moderna's revenue has significantly declined post-pandemic, with 2022 sales of $19.3 billion dropping to just $3.2 billion in 2024, reflecting a more than 50% year-over-year decline [2] - The company has lowered its sales guidance for 2025 to a range of $1 billion, down from previous expectations of $2.5 billion to $3.5 billion, indicating weakened demand for its vaccines [3] Financial Performance - Moderna's sales have plummeted since the pandemic, with a stark contrast between 2022 and 2024 figures [2] - The company is now projecting sales for 2025 to be between $1.5 billion and $2.5 billion, a significant reduction from earlier forecasts [3] Cost-Cutting Measures - In response to declining revenues, Moderna is accelerating cost-cutting plans aimed at reducing expenses by $1 billion in 2025 [4] Regulatory Environment - The resignation of Peter Marks, a key FDA official, has raised concerns among investors, as it may lead to delays in vaccine development programs [5][6] - The political climate surrounding the FDA has been described as a "significant negative" for biotech and biopharma companies, particularly for vaccine manufacturers like Moderna [6]

Core Insights - Pfizer and Moderna were the two leading companies in developing effective coronavirus vaccines, achieving significant financial success during the pandemic [1] - Both companies have experienced a substantial decline in revenue and share prices as the pandemic has receded, raising questions about their future performance [2] Pfizer - Pfizer has made strategic moves, including the approval of new medicines and vaccines, and a significant acquisition of Seagen for $43 billion, enhancing its oncology pipeline [3] - In 2024, Pfizer reported a revenue of $63.6 billion, a 7% increase from the previous year, with adjusted earnings per share of $3.11, reflecting a 69% year-over-year growth [4] - The company continues to generate sales from its COVID-19 products, Comirnaty and Paxlovid, which contributed approximately $11.1 billion in sales in 2024 [4] - Pfizer is expected to navigate upcoming patent cliffs successfully, supported by its ongoing product approvals and a strong dividend yield of 6.8%, with a 53.6% increase in payouts over the past decade [5][6] Moderna - Moderna's total revenue in 2024 fell nearly 53% year-over-year to $3.2 billion, with a net loss per share of $9.28, although this was an improvement from the previous year's loss [7] - The company has received approval for an RSV vaccine and is awaiting further label expansions, indicating potential growth opportunities [8] - Moderna's combination COVID/influenza vaccine showed promising results in a phase 3 study, and the company is pursuing multiple late-stage studies for innovative products, including a personalized cancer vaccine [9][10] - The mRNA platform has demonstrated success, and if Moderna continues to achieve positive clinical results and regulatory approvals, its financial performance may improve [10] Comparative Analysis - Pfizer is characterized as a well-established pharmaceutical giant with consistent revenue from a diverse product portfolio, while Moderna is a smaller biotech company with fewer profitable products [11] - Pfizer outperforms Moderna in key financial metrics such as total sales, profits, and free cash flow, and it also offers dividends, making it attractive for income-seeking investors [12] - While Pfizer is viewed as the better investment option for most investors, Moderna may present higher upside potential for those willing to accept greater risk and volatility [13]

Core Viewpoint - Moderna is attempting to diversify its product offerings beyond its coronavirus vaccine, with a full pipeline of programs in various therapeutic areas, including cancer, despite facing significant stock price declines and regulatory uncertainties [1][5][12]. Financial Performance - Moderna experienced a dramatic increase in earnings during the early pandemic, generating over $19 billion in revenue at its peak in 2022, but reported only $3.2 billion in revenue last year, resulting in a GAAP loss of $3.6 billion [3][4]. Product Pipeline - The company has launched a second product, an RSV vaccine, but sales have not met expectations. Moderna aims to introduce up to 10 new products utilizing its mRNA technology by 2027, which could significantly impact its financial performance [5][12]. Regulatory Environment - The recent resignation of Peter Marks from the FDA has created uncertainty regarding the regulatory landscape for vaccines, which is critical for Moderna as it prepares for multiple vaccine approval requests [6][9]. - Marks' departure is linked to disagreements with the new HHS Secretary, raising concerns about the future of vaccine funding and development under the current administration [8][9]. Market Sentiment - Moderna's stock has fallen 74% over the past year, reflecting investor skepticism amid the changing regulatory environment and recent leadership changes at the FDA [2][4]. - Despite the current challenges, there is optimism about the potential of Moderna's pipeline, suggesting that it may be a suitable long-term investment for aggressive investors [12].

Shares of Moderna (MRNA -9.19%) are falling on Monday. The company's stock lost 7.9% as of 1:30 p.m. ET and was down as much as 13.9% earlier in the day. The steep decline comes as the S&P 500 and Nasdaq Composite lost 0.4% and 1.1%, respectively. The vaccine maker's shares tumbled following the resignation of a key U.S. Food and Drug Administration (FDA) official who oversaw vaccine approvals. The top FDA vaccine regulator leaves Peter Marks, who led the FDA's Center for Biologics Evaluation and Research ( ...

Core Viewpoint - Moderna's stock has been trending recently, with a return of -3.8% over the past month, outperforming the Zacks S&P 500 composite's -7.5% change, while the Zacks Medical - Biomedical and Genetics industry saw a loss of 0.6% [1] Earnings Estimates Revisions - For the current quarter, Moderna is expected to report a loss of $2.90 per share, reflecting a change of +5.5% from the same quarter last year, with the Zacks Consensus Estimate changing by +0.5% over the last 30 days [4] - The consensus earnings estimate for the current fiscal year is -$10.03, indicating a change of -13.1% from the previous year, with a recent change of -4.3% [4] - For the next fiscal year, the consensus estimate of -$7.02 shows a change of +29.9% from the prior year, with an increase of +6.6% over the past month [5] Revenue Growth Forecast - The consensus sales estimate for the current quarter is $142.28 million, indicating a year-over-year change of -14.8% [8] - For the current fiscal year, the sales estimate is $2.2 billion, reflecting a change of -31.9%, while the next fiscal year's estimate of $3.01 billion indicates a change of +36.7% [8] Last Reported Results and Surprise History - In the last reported quarter, Moderna's revenues were $966 million, representing a year-over-year decline of -65.6%, with an EPS of -$2.50 compared to $0.55 a year ago [9] - The reported revenues exceeded the Zacks Consensus Estimate of $956.11 million by +1.04%, and the EPS surprise was +7.06% [10] - Moderna has consistently beaten consensus EPS and revenue estimates in the trailing four quarters [10] Valuation - Moderna is graded F in the Zacks Value Style Score, indicating it is trading at a premium compared to its peers [14] - Valuation multiples such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF) are essential for determining whether the stock is overvalued, fairly valued, or undervalued [12][13] Bottom Line - The current Zacks Rank of 3 suggests that Moderna may perform in line with the broader market in the near term, despite the market buzz surrounding the company [15]